Revolution stalled.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 23052291.
- Also identified by DOI 10.1126/scitranslmed.3003142.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Drug discovery is at a near standstill for treating psychiatric disorders such as schizophrenia, bipolar disorder, depression, and common forms of autism. Despite high prevalence and unmet medical need, major pharmaceutical companies are deemphasizing or exiting psychiatry, thus removing significant capacity from efforts to discover new medicines. In this Commentary, I develop a view of what has gone wrong scientifically and ask what can be done to address this parlous situation.
Medical subject headings
- Autistic Disorder
- Autistic Disorder/drug therapy
- Autistic Disorder/metabolism
- Bipolar Disorder
- Bipolar Disorder/drug therapy
- Bipolar Disorder/metabolism
- Drug Discovery
- Humans
- Pharmaceutical Preparations
- Schizophrenia
- Schizophrenia/drug therapy
- Schizophrenia/metabolism